HK1218709A1 - 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法 - Google Patents

新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法

Info

Publication number
HK1218709A1
HK1218709A1 HK16106053.3A HK16106053A HK1218709A1 HK 1218709 A1 HK1218709 A1 HK 1218709A1 HK 16106053 A HK16106053 A HK 16106053A HK 1218709 A1 HK1218709 A1 HK 1218709A1
Authority
HK
Hong Kong
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
acid derivatives
salicylic acid
Prior art date
Application number
HK16106053.3A
Other languages
English (en)
Inventor
梅利莎．
．菲謝爾
帕特里克．托馬斯．貢寧
西納．哈夫特舍納里
布倫特．戴維．喬治．帕蓋
塞謬爾．韋斯
赫馬．阿蒂．盧奇曼
Original Assignee
Governing Council Univ Toronto
Uti Limited Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Governing Council Univ Toronto, Uti Limited Partnership filed Critical Governing Council Univ Toronto
Publication of HK1218709A1 publication Critical patent/HK1218709A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
HK16106053.3A 2012-05-25 2016-05-27 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法 HK1218709A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651757P 2012-05-25 2012-05-25
PCT/US2013/042689 WO2013177534A2 (en) 2012-05-25 2013-05-24 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Publications (1)

Publication Number Publication Date
HK1218709A1 true HK1218709A1 (zh) 2017-03-10

Family

ID=49624538

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106053.3A HK1218709A1 (zh) 2012-05-25 2016-05-27 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法

Country Status (9)

Country Link
US (3) US9650399B2 (zh)
EP (1) EP2854819B1 (zh)
JP (2) JP6290871B2 (zh)
CN (2) CN105120854B (zh)
BR (1) BR112014029439A2 (zh)
CA (1) CA2874057A1 (zh)
HK (1) HK1218709A1 (zh)
RU (1) RU2641903C2 (zh)
WO (1) WO2013177534A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9802888B2 (en) * 2013-03-22 2017-10-31 University Of Hawaii STAT3 inhibitors
JP6594908B2 (ja) * 2014-05-30 2019-10-23 ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント スルホンアミド化合物およびそのｓｔａｔ５阻害剤としての使用
EP3570836A4 (en) * 2017-01-23 2020-08-19 The University of Hawaii 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS
EP3898582A4 (en) * 2018-12-21 2022-08-24 The Governing Council of the University of Toronto NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
KR20220006139A (ko) 2019-04-05 2022-01-14 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
JP2023515236A (ja) * 2020-03-05 2023-04-12 ジャンピックス，エルティーディ． α置換されたＳＴＡＴ阻害剤およびその組成物
CN115551496A (zh) * 2020-03-05 2022-12-30 詹皮克斯有限公司 Stat抑制性化合物和组合物
CN112941036B (zh) * 2021-02-08 2023-06-09 吉林惠康生物药业有限公司 一种提高狂犬病毒在人二倍体细胞中复制水平的方法
CN114751927B (zh) * 2022-03-08 2023-10-31 中山大学 一种硼酸化合物、制备方法及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385831T3 (es) * 2003-12-11 2012-08-01 Board Of Regents, The University Of Texas System Compuestos para el tratamiento de enfermedades celulares proliferativas
WO2007115269A2 (en) * 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
WO2007136858A2 (en) 2006-05-19 2007-11-29 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of stat3 with anti-tumor activity
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
NZ590355A (en) * 2008-07-10 2013-01-25 Yakult Honsha Kk Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
CA2757912A1 (en) 2009-04-06 2010-10-14 University Of Central Florida Research Foundation, Inc. Compounds that suppress cancer cells and exhibit antitumor activity
JP2013537535A (ja) * 2010-08-02 2013-10-03 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド Ｓｔａｔタンパク質の阻害剤としての、置換２−ヒドロキシ−４−（２−（フェニルスルホンアミド）アセトアミド）安息香酸類似体
US9802888B2 (en) * 2013-03-22 2017-10-31 University Of Hawaii STAT3 inhibitors

Also Published As

Publication number Publication date
JP2015522551A (ja) 2015-08-06
BR112014029439A2 (pt) 2017-06-27
EP2854819A2 (en) 2015-04-08
CN110003104A (zh) 2019-07-12
CN105120854A (zh) 2015-12-02
US20150158894A1 (en) 2015-06-11
CN105120854B (zh) 2019-04-09
RU2014152697A (ru) 2016-07-20
WO2013177534A2 (en) 2013-11-28
US20190382422A1 (en) 2019-12-19
CA2874057A1 (en) 2013-11-28
JP6290871B2 (ja) 2018-03-07
US20170267704A1 (en) 2017-09-21
EP2854819B1 (en) 2020-01-15
JP2018109017A (ja) 2018-07-12
US10377780B2 (en) 2019-08-13
JP6543366B2 (ja) 2019-07-10
US9650399B2 (en) 2017-05-16
RU2641903C2 (ru) 2018-01-23
EP2854819A4 (en) 2016-06-15
WO2013177534A3 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
HK1218709A1 (zh) 新水楊酸衍生物、其藥學上可接受的鹽、其組合物以及其使用方法
IL233200A0 (en) The history of alpha-boronic acid, its preparation and pharmaceutical preparations containing it
PL2882779T3 (pl) Pochodna kwasu hialuronowego, sposób jej wytwarzania, sposób jej modyfikacji i jej zastosowanie
EP2881395A4 (en) PIPERAZINOTRIZOLE COMPOUND, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN THE PREPARATION OF MEDICAMENT
HUE038664T2 (hu) Hialuronsav C6-C18-acilezett származéka, eljárás annak elõállítására, erre épülõ nanomicelláris kompozíció, eljárás annak elõállítására és eljárás stabilizált nanomicelláris kompozíció elõállítására, valamint annak alkalmazása
HK1206264A1 (zh) 犬尿氨酸- -單加氧酶抑制劑、其藥物組合物及其使用方法
IL250370A0 (en) Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals
IL249826A0 (en) Propionic acid derivatives converted in 3-heteroylamino and their use in pharmaceutical preparations
IL225972A0 (en) Salts of cocuamine b, a method for their preparation and use
ZA201400188B (en) Substituted cinnamamide derivative, preparation method and use thereof
EP2576576A4 (en) HETEROCYCLYL-PYRIDINYL BASE PHOSPHONIC ACID, PHARMACEUTICALLY ALLOWED SALT, COMPOSITION, AND METHOD OF USE THEREOF
HK1187335A1 (zh) 氨基取代的 -雜芳酰基氨基-丙酸衍生物及其作為藥物的用途
EP2888260A4 (en) SUBSTITUTED AZAINDOLE COMPOUNDS, THEIR SALTS, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
EP2927226A4 (en) MONOHYDRATE CRYSTAL FROM FIMASARTANKALIUM SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACOLOGICAL COMPOSITION THEREWITH
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
HK1188791A1 (zh) 新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
EP2805956A4 (en) GAMBOGIC ACID DERIVATIVES, PREPARATION METHOD AND APPLICATION THEREOF
TWI559918B (en) Use of gallic acid and its pharmaceutically acceptable salt
IL230907A0 (en) Salt and formations of a pyrazolopyrimidine compound, a medical composition that includes the above, and a preparation and use process for them
PL399613A1 (pl) Pochodne estrów diarylowych kwasów 1-aminoalkanofosfonowych, sposób wytwarzania pochodnych estrów diarylowych kwasów 1-aminoalkanofosfonowych oraz ich zastosowanie
IL238934A0 (en) Methods for the preparation of phenyloxymethyl-nitro-imidazole derivatives and their use